Cargando…

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

BACKGROUND: Given the importance of neutralising antibodies in protection against SARS-CoV-2 infection, it is critical to assess neutralisation persistence long-term following recovery. This study investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Underwood, Alexander P., Sølund, Christina, Fernandez-Antunez, Carlota, Villadsen, Signe Lysemose, Winckelmann, Anni Assing, Bollerup, Signe, Mikkelsen, Lotte S., Sørensen, Anna-Louise, Feng, Shan, Fahnøe, Ulrik, Lassauniere, Ria, Fomsgaard, Anders, Ramirez, Santseharay, Weis, Nina, Bukh, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375401/ https://www.ncbi.nlm.nih.gov/pubmed/34419923 http://dx.doi.org/10.1016/j.ebiom.2021.103519

Ejemplares similares

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
por: Underwood, Alexander P., et al.
Publicado: (2023)

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines
por: Sølund, Christina, et al.
Publicado: (2022)

In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms
por: Lassaunière, Ria, et al.
Publicado: (2021)

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
por: Ramirez, Santseharay, et al.
Publicado: (2021)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

The Role of CTLA-4 in T Cell Exhaustion in Chronic Hepatitis B Virus Infection
por: Apol, Ása Didriksen, et al.
Publicado: (2023)

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
por: Fahnøe, Ulrik, et al.
Publicado: (2022)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
por: Nguyen, Dung, et al.
Publicado: (2021)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021
por: Lassaunière, Ria, et al.
Publicado: (2021)

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro
por: Zhou, Yuyong, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system
por: Galli, Andrea, et al.
Publicado: (2021)

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
por: Zhou, Yuyong, et al.
Publicado: (2022)

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

A Candidate DNA Vaccine Encoding the Native SARS-CoV-2 Spike Protein Induces Anti-Subdomain 1 Antibodies
por: Frische, Anders, et al.
Publicado: (2023)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
por: Jensen, Sanne Brun, et al.
Publicado: (2019)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
por: Cromer, Deborah, et al.
Publicado: (2022)

Sero-Monitoring of Horses Demonstrates the Equivac(®) HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres
por: Halpin, Kim, et al.
Publicado: (2021)

Psychological Distress among Hospitalized COVID-19 Patients in Denmark during the First 12 Months of the Pandemic
por: Moseholm, Ellen, et al.
Publicado: (2022)

Nationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations
por: Sølund, Christina, et al.
Publicado: (2014)

Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein
por: Jaberolansar, Noushin, et al.
Publicado: (2017)

SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
por: Lumley, Sheila F, et al.
Publicado: (2020)

Socioeconomic predictors of human papillomavirus vaccination in Danish men – A nationwide study
por: Bollerup, Signe, et al.
Publicado: (2016)

Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1–3 Strains and Does Not Correlate with Virus Replication
por: Galli, Andrea, et al.
Publicado: (2021)

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
por: Lassaunière, Ria, et al.
Publicado: (2022)

Temporally separated feline calicivirus isolates do not cluster phylogenetically and are similarly neutralised by high-titre vaccine strain FCV-F9 antisera in vitro
por: Smith, Shirley L, et al.
Publicado: (2019)

Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection
por: Fossat, Nicolas, et al.
Publicado: (2023)

Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment
por: Pedersen, Martin S., et al.
Publicado: (2021)

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
por: Zhou, Yuyong, et al.
Publicado: (2021)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
por: Offersgaard, Anna, et al.
Publicado: (2023)

SARS-CoV-2 Y453F is not the “cluster 5” variant
por: Lassaunière, Ria
Publicado: (2021)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021
por: Woudenberg, Tom, et al.
Publicado: (2023)

Amantadine for COVID-19 treatment (ACT study): a randomized, double-blinded, placebo-controlled clinical trial
por: Weis, Nina, et al.
Publicado: (2023)

Neutralisation and the brickwall
por: Hereward, H G
Publicado: (1974)

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study
por: Spinelli, Matthew A, et al.
Publicado: (2021)

FcγR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations
por: Lassaunière, Ria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_du099k677sqn2s98uvo080fr77